FDA, EU Likely to Boost Use of Special Designations in 2013: Tufts

U.S. and EU regulators hope to increase the use of special designations, such as fast track, priority review and accelerated approval, to speed approvals of drugs for non-cancer diseases that are rare and/or life-threatening, according to a new Tufts report. Regulators want to approve these products at the same levels oncology drugs enjoyed between 2007 and 2011.
Washington Drug Letter